Segment Information
The Company manages its operations as a single operating and reportable segment with a focus on developing and commercializing novel oncolytic immunotherapies in order to treat cancer. The Company defines its segments on the basis of the way in which internally reported financial information is regularly reviewed to analyze financial performance and make operating decisions. The Company’s Chief Operating Decision Maker ("CODM") is Sushil Patel, the Chief Executive Officer. The CODM reviews consolidated operating results, and uses the Company's consolidated net income (loss), in order to monitor actual results as compared to the budget, and to determine how best to allocate the Company's operating and capital resources, specifically as it relates to the Company's development programs.
The following table presents selected financial information with respect to the Company's single operating segment, including significant segment expenses by program, for the years ended March 31, 2025 and 2024:

Year Ended March 31,
20252024
Operating expenses:(Amounts in thousands)
Direct research and development expenses by program:
       RP1 program costs by study:
  IGNYTE14,620 16,641 
  ARTACUS6,934 6,198 
  CERPASS7,276 16,165 
  IGNYTE-37,183 2,042 
  Other RP1 study costs10,863 10,446 
RP212,043 10,701 
RP34,948 13,162 
Unallocated research and development expenses¹:125,580 99,608 
Selling, general and administrative72,180 59,810 
Total operating expenses261,627 234,773 
Loss from operations(261,627)(234,773)
Other income (expense), net14,798 $19,387 
Loss before income taxes$(246,829)$(215,386)
Income tax provision468 408 
Net loss(247,297)(215,794)
1Includes personnel-related costs and other costs

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.